Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 391

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 391
---
We lease approximately 17,700
square feet of office space in Nashville, Tennessee. The current lease term expires on June 30, 2032 and includes the option to extend
the term for two additional, consecutive five-year terms. This office serves as our corporate headquarters.

We lease approximately 38,200
square feet of lab, warehouse, and office space in Ledgewood, New Jersey, in three separate suites. The current lease term expires on
July 31, 2027 and includes options to extend the lease term through 2037. This space serves as an outsourcing facility and pharmacy for
ImprimisRx.

We lease approximately 11,600
square feet of lab and office space in Nashville, Tennessee. The current lease term commenced in June 2022 and expires in June 2027.
This office generally serves as ImprimisRx’s customer service center and analytical laboratory.

We lease approximately 5,800
square feet of office space in Carlsbad, California. The current lease term began January 1, 2022 and expires on March 31, 2025 and includes
an option to extend the lease term through March 2028. This office generally supports the certain marketing and administrative functions.
We notified our landlord that we will not renew this lease upon expiration of its initial term on March 31, 2025.

ITEM 3. LEGAL PROCEEDINGS

See Note 18 to our
consolidated financial statements included in this Annual Report for information on various legal proceedings, which is incorporated
into this Item by reference. Additionally, we have been in discussions with the federal government regarding past inspections at
NJOF. For information regarding these discussions see Part I, Item 1A. “Risk Factors – We have been in discussions
with the federal government regarding past FDA inspections of our 503B facility, and to the extent we are unable to demonstrate
compliance with cGMPs and other required regulations, the government could seek injunctive remedies, including through a consent
decree and temporary injunction, the effects of which could be costly to us and could result in adverse consequences to our
business.”

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY,
RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is listed on
The Nas